Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) Target Price at $63.73

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $63.73.

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, March 12th. Morgan Stanley reissued an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. JPMorgan Chase & Co. decreased their price objective on Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a report on Monday. Finally, Mizuho dropped their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research note on Monday, April 7th.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunocore

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. purchased a new position in Immunocore in the fourth quarter valued at $25,000. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC grew its stake in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC purchased a new stake in shares of Immunocore in the fourth quarter valued at approximately $330,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Trading Up 1.9 %

Shares of NASDAQ IMCR opened at $28.41 on Tuesday. Immunocore has a 1-year low of $23.15 and a 1-year high of $62.74. The business has a fifty day moving average price of $28.74 and a 200 day moving average price of $30.40. The stock has a market capitalization of $1.42 billion, a P/E ratio of -29.90 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.